NCT04745091

Brief Summary

Patients with middle or low rectal cancer who receive neoadjuvant chemoradiation and achieve complete clinical response while their pelvic MRI have split scar sign are included. Patients will have total mesorectal excision and pathologic complete response will be assessed

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2021

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 30, 2021

Completed
2 days until next milestone

Study Start

First participant enrolled

February 1, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 9, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
Last Updated

February 9, 2021

Status Verified

January 1, 2021

Enrollment Period

11 months

First QC Date

January 30, 2021

Last Update Submit

February 6, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Complete pathologic response

    disappearance of tumor from resected specimen

    after surgical excision with follow up of an average of 1 year

Interventions

excision of the rectum with complete excision of the mesorectum

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

locally advance middle and low rectal cancer

You may qualify if:

  • middle and low rectal cancer

You may not qualify if:

  • Distant metastasis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

rectal cancer specimens

MeSH Terms

Conditions

Rectal Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Khaled Madbouly, MD, PhD

    University of Alexandria

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Khaled Madbouly, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Surgery

Study Record Dates

First Submitted

January 30, 2021

First Posted

February 9, 2021

Study Start

February 1, 2021

Primary Completion

December 31, 2021

Study Completion

June 30, 2022

Last Updated

February 9, 2021

Record last verified: 2021-01